PerkinElmer Inc at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual) Transcript
Hi. This is Paul Knight, the analyst at KeyBanc on the life science industry. With me today, had been covering PerkinElmer, which I have followed since 1999 when they were known as EG&G, which, again, fast forward, I think, Steve, there will be no longer PerkinElmer soon. But Steve Willoughby, Director of Investor Relations; Alan Fletcher, Head of the Life Science Group. But Steve, I think if you could provide a little bit of intro yourself and for Alan, that would be a good place to start.
Very good. Yes. Paul, thanks for having us. Happy to be here. So Steve Willoughby, I lead IR as well as ESG for the company. I've been here just about 2 years, after also being on the sell side for nearly 20 years before joining the corporate side. And so I've also known the company not since '99, but for quite a while, externally and then, obviously, for the last 2 years on this side of the fence.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |